TD Cowen Initiates Coverage On Cartesian Therapeutics with Buy Rating
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Buy rating, as announced by analyst Tyler Van Buren.
August 06, 2024 | 9:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has initiated coverage on Cartesian Therapeutics with a Buy rating, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating by a reputable analyst can lead to increased investor interest and buying activity, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100